➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
Baxter
AstraZeneca
Dow
Colorcon

Last Updated: February 28, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR GAZYVA

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for GAZYVA

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02100852 TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL) Active, not recruiting TG Therapeutics, Inc. Phase 1 2014-03-01 The purpose of this study is to evaluate the safety and effectiveness of TGR-1202 in combination with obinutuzumab (Gazyva) and chlorambucil in patients with chronic lymphocytic leukemia.
NCT02225275 Combination of Lenalidomide and Obinutuzumab (GA101) in Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Recruiting Celgene Corporation Phase 2 2016-03-01 The goal of this clinical research study is to learn if the combination of lenalidomide and obinutuzumab can help to control CLL or SLL. The safety of this drug combination will also be studied.
NCT02225275 Combination of Lenalidomide and Obinutuzumab (GA101) in Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Recruiting Genentech, Inc. Phase 2 2016-03-01 The goal of this clinical research study is to learn if the combination of lenalidomide and obinutuzumab can help to control CLL or SLL. The safety of this drug combination will also be studied.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for GAZYVA

Condition Name

Condition Name for GAZYVA
Intervention Trials
Chronic Lymphocytic Leukemia 16
Small Lymphocytic Lymphoma 6
Refractory Chronic Lymphocytic Leukemia 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for GAZYVA
Intervention Trials
Lymphoma 26
Leukemia, Lymphocytic, Chronic, B-Cell 24
Leukemia, Lymphoid 24
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for GAZYVA

Trials by Country

Trials by Country for GAZYVA
Location Trials
United States 117
Italy 12
Australia 8
Spain 5
Canada 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for GAZYVA
Location Trials
Texas 12
California 9
New York 7
Massachusetts 7
Ohio 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for GAZYVA

Clinical Trial Phase

Clinical Trial Phase for GAZYVA
Clinical Trial Phase Trials
Phase 3 8
Phase 2 22
Phase 1/Phase 2 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for GAZYVA
Clinical Trial Phase Trials
Not yet recruiting 25
Recruiting 21
Active, not recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for GAZYVA

Sponsor Name

Sponsor Name for GAZYVA
Sponsor Trials
Genentech, Inc. 13
National Cancer Institute (NCI) 13
M.D. Anderson Cancer Center 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for GAZYVA
Sponsor Trials
Other 39
Industry 36
NIH 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
AstraZeneca
Express Scripts
McKinsey
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.